"Caring Cognitive Behavioral Therapy Psychologists providing treatment for a wide range of issues for Adults, Young Adults, Teens and Children."

During the past decade, Neuroscience, Inc. conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 21 clinical trials were completed, i.e. on average, 175% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 4 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Neuroscience, Inc." #1 sponsor was "Shire" with 14 trials, followed by "Sunovion" with 7 trials sponsored, "Otsuka Pharmaceutical Development & Commercialization, Inc." with 4 trials sponsored, "Noven Therapeutics" with 3 trials sponsored and "Rhodes Pharmaceuticals, L.P." with 3 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Neuroscience, Inc." #1 collaborator was "Pfizer" with 2 trials as a collaborator, "Purdue Pharma LP" with 2 trials as a collaborator, "Noven Pharmaceuticals, Inc." with 1 trials as a collaborator, "Otsuka America Pharmaceutical" with 1 trials as a collaborator and "Purdue Pharma, Canada" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Neuroscience, Inc." are "ADHD" (9 trials), "Attention Deficit Hyperactivity Disorder" (4 trials), "Attention Deficit Hyperactivity Disorder (ADHD)" (4 trials), "Autism" (4 trials) and "Binge Eating Disorder" (4 trials). Many other conditions were trialed in "Neuroscience, Inc." in a lesser frequency.

Most popular intervention types in "Neuroscience, Inc." are "Drug" (43 trials) and "Other" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "Dasotraline" (4 trials), "ADT" (3 trials), "OPC-34712" (3 trials) and "CM-AT" (2 trials). Other intervention names were less common.

The vast majority of trials in "Neuroscience, Inc." are 43 trials for "All" genders.

Currently, there are NaN active trials in "Neuroscience, Inc.". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 39 completed trials in Neuroscience, Inc., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Neuroscience, Inc., 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".